2018
Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade
Metzger‐Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, Vaz‐Luis I, Hughes ME, Winer EP, Lin NU. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. The Oncologist 2018, 24: e441-e449. PMID: 30518616, PMCID: PMC6656459, DOI: 10.1634/theoncologist.2018-0363.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaDisease-free survivalHistologic gradeLobular carcinomaPostmenopausal womenSystemic therapyBetter prognosisAromatase inhibitorsPrognostic powerDisease-free survival advantageEarly-stage breast cancerFavorable disease-free survivalCox proportional hazards modelAdjuvant aromatase inhibitorsBaseline clinicopathologic characteristicsDetailed clinical databaseHER2-negative diseaseRetrospective cohort studyImportant prognostic factorKaplan-Meier methodProportional hazards modelIntermediate histologic gradeDistinct disease subtypesCohort studyOverall prognosis
2016
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis
Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research And Treatment 2016, 157: 587-596. PMID: 27271765, DOI: 10.1007/s10549-016-3845-5.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerMedian overall survivalOverall survivalPopulation-based analysisDuctal carcinomaLobular carcinomaAnnual percent changeBreast cancerIncidence rateDe novo metastatic breast cancerEnd Results 9 registriesHormone receptor-positive tumorsNovo metastatic breast cancerMultivariable Cox regression modelsStage IV breast cancerAnnual age-adjusted incidence ratesAge-adjusted incidence ratesAdjusted hazard ratioBetter overall survivalDate of diagnosisReceptor-positive tumorsBreast cancer incidenceCox regression modelHazard ratioTumor histology
2015
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, Thürlimann B, Gelber RD, Colleoni M, Ejlertsen B, Debled M, Price KN, Regan MM, Coates AS, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal Of Clinical Oncology 2015, 33: 2772-2779. PMID: 26215945, PMCID: PMC4550691, DOI: 10.1200/jco.2015.60.8133.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansKi-67 AntigenLetrozoleMiddle AgedNitrilesReceptor, ErbB-2TamoxifenTreatment OutcomeTriazolesConceptsInvasive ductal carcinomaInvasive lobular carcinomaDisease-free survivalLobular carcinomaDFS eventsDuctal carcinomaLA subtypeBreast International Group (BIG) 1Early-stage invasive ductal carcinomaClassic invasive lobular carcinomaHER2-negative invasive ductal carcinomaKi-67 labeling indexLow proliferative activityMagnitude of benefitAdjuvant letrozoleMedian followBIG 1ILC subsetsMultivariable modelCox modelGroup 1LetrozoleCarcinomaLabeling indexPatientsSurgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast
Sagara Y, Barry WT, Mallory MA, Vaz-Luis I, Aydogan F, Brock JE, Winer EP, Golshan M, Metzger-Filho O. Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. Annals Of Surgical Oncology 2015, 22: 4280-4286. PMID: 25893416, PMCID: PMC4801503, DOI: 10.1245/s10434-015-4570-8.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceBreast-conserving surgeryInitial breast-conserving surgeryLocoregional recurrenceMargin statusLobular carcinomaBreast tumor recurrenceRetrospective cohort studyPositive surgical marginsInvasive lobular carcinomaMedian followInitial surgeryMultimodality therapyCohort studyFurther surgeryAdditional surgeryClinicopathologic dataSurgical marginsSurgical optionsNegative marginsTumor sizeCancer CenterClose marginsConsensus guidelinesTumor recurrence
2013
Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.
Metzger Filho O, Giobbie-Hurder A, Mallon E, Viale G, Winer E, Thurlimann B, Gelber R, Regan M, Colleoni M, Ejlertsen B, Bonnefoi H, Forbes J, Neven P, Wardley A, Lang I, Smith I, Price K, Coates A, Goldhirsch A. Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma. Journal Of Clinical Oncology 2013, 31: 529-529. DOI: 10.1200/jco.2013.31.15_suppl.529.Peer-Reviewed Original ResearchMagnitude of benefitMonotherapy armYears of tamoxifenPost-menopausal womenInvasive lobular carcinomaILC patientsBetter DFSBIG 1Early BCClinicopathological variablesHistological subtypesLobular carcinomaILC subsetsPatientsTreatment assignmentDFSSignificant predictorsTamoxifenHistologyIDCGreater magnitudeClassic ILCOSArmPrevious data